Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE

By sjmartinez • May 29, 2023

Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. Br J Haematol. 2023 May 29. doi: 10.1111/bjh.18883. Epub ahead of print. PMID: 37246588.

Tags: chronic phase chronic myeloid leukaemia, dasatinib, deep molecular response, Hematology/Oncology, major molecular response, Publications, treatment-free remission

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer

Karunanandaa K, Knoche EM, Montgomery RB, Pickett C, Doherty J, Gruber J, Raychaudhuri R, Eaton D, Garraway IP, Rettig M, Maxwell KN, Schoen MW. Tumor[...]

B Cell Receptor’s function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism

Larios R, Hossain MB, Brown R, Jeyachandran AV, Abu AE, Zaiss AK, Ramirez CM, Kamata M, Cole S, Wu TT, Dorshkind K, Arumugaswami V, Morizono[...]

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Landon BV, Boland JL, Wahner Hendrickson AE, Armstrong DK, Winterhoff B, Wehr J, Annapragada AV, Cherry C, Balan A, Kaleka G, Velculescu VE, Baylin SB,[...]